The DOI matches its Crossref record; 165 of the 165 references it cites were found in a registry or an index.
Chemical Inhibitors of Protein Kinases
Abstract
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTChemical Inhibitors of Protein KinasesAlexander J. BridgesView Author Information Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, Michigan 48105 Cite this: Chem. Rev. 2001, 101, 8, 2541–2572Publication Date (Web):July 4, 2001Publication History Received30 October 2000Published online4 July 2001Published inissue 1 August 2001https://pubs.acs.org/doi/10.1021/cr000250yhttps://doi.org/10.1021/cr000250yresearch-articleACS PublicationsCopyright © 2001 American Chemical SocietyRequest reuse permissionsArticle Views2896Altmetric-Citations273LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Assays,Cancer,Inhibitors,Peptides and proteins,Pharmaceuticals Get e-Alerts
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Intracellular Signaling by Hydrolysis of Phospholipids and Activation of Protein Kinase C
Nishizuka, Y. (1992) · Science · doi:10.1126/science.1411571 · Cited by 4,472
The molecular heterogeneity of protein kinase C and its implications for cellular regulation
Nishizuka, Y. (1988) · Nature · doi:10.1038/334661a0 · Cited by 4,171
Genistein, a specific inhibitor of tyrosine-specific protein kinases.
Akiyama, T., Ishida, J., Nakagawa, S., Ogawara, H., Watanabe, S., Itoh, N., Shibuya, M., & Fukami, Y. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45614-1 · Cited by 3,724
Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27489 · Cited by 3,393
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Protein kinase C and lipid signaling for sustained cellular responses
Nishizuka, Y. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.7.7737456 · Cited by 2,499
Staurosporine, a potent inhibitor of phospholipidCa++dependent protein kinase
Tamaoki, T., Nomoto, H., Takahashi, I., Kato, Y., Morimoto, M., & Tomita, F. (1986) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(86)90008-2 · Cited by 2,452
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
Stebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., & Pavletich, N. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80203-2 · Cited by 1,364
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Protein kinase C activation and the development of diabetic complications.
Koya, D., & King, G. L. (1998) · Diabetes · doi:10.2337/diabetes.47.6.859 · Cited by 1,330
CRM1 is responsible for intracellular transport mediated by the nuclear export signal
Fukuda, M., Asano, S., Nakamura, T., Adachi, M., Yoshida, M., Yanagida, M., & Nishida, E. (1997) · Nature · doi:10.1038/36894 · Cited by 1,211
Heinrich, M. C., Griffith, D. J., Druker, B. J., Wait, C. L., Ott, K. A., & Zigler, A. J. (2000) · Blood · doi:10.1182/blood.v96.3.925 · Cited by 1,071
Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Druker, B. J., & Lydon, N. (1996) · PubMed · Cited by 1,057
Roe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980403y · Cited by 1,004
Activation of the zeta isozyme of protein kinase C by phosphatidylinositol 3,4,5-trisphosphate.
Nakanishi, H., Brewer, K. A., & Exton, J. H. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)54107-7 · Cited by 965
Protein kinase C - a question of specificity
Dekker, L. V., & Parker, P. J. (1994) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(94)90038-8 · Cited by 944
Ciardiello, F., Caputo, R., Bianco, R., Damiano, Pomatico, G., De Placido, S., Bianco, A. R., & Tortora, G. (2000) · PubMed · Cited by 943
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage
Gong, J., Costanzo, A., Yang, H.-Q., Melino, G., Kaelin, W. G., Levrero, M., & Wang, J. Y. J. (1999) · Nature · doi:10.1038/21690 · Cited by 930
BindingDB (2025) · PubMed · doi:10.7270/q2dr317m · Cited by 843
The Epidermal Growth Factor Receptor and Its Inhibition in Cancer Therapy
Woodburn, J. R. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00045-x · Cited by 827
Druker, B. J., & Lydon, N. B. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9083 · Cited by 707
Pendergast, A. M., Quilliam, L. A., Cripe, L. D., Bassing, C. H., Dai, Z., Li, N., Batzer, A., Rabun, K. M., Der, C. J., Schlessinger, J., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90689-n · Cited by 659
Zhang, G., Kazanietz, M. G., Blumberg, P. M., & Hurley, J. H. (1995) · Cell · doi:10.1016/0092-8674(95)90011-x · Cited by 652
Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors
Gazit, A., Yaish, P., Gilon, C., & Levitzki, A. (1989) · Journal of Medicinal Chemistry · doi:10.1021/jm00130a020 · Cited by 600
Takai, Y., Kishimoto, A., Inoue, M., & Nishizuka, Y. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41009-x · Cited by 595
Zheng, J., Knighton, D. R., Ten Eyck, L. F., Karlsson, R., Xuong, N., Taylor, S. S., & Sowadski, J. M. (1993) · Biochemistry · doi:10.1021/bi00060a005 · Cited by 589
p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage
Yuan, Z.-M., Shioya, H., Ishiko, T., Sun, X., Gu, J., Huang, Y., Lu, H., Kharbanda, S., Weichselbaum, R., & Kufe, D. (1999) · Nature · doi:10.1038/21704 · Cited by 578
Skorski, T., Bellacosa, A., Nieborowska‐Skorska, M., Majewski, M., Martinez, R., Choi, J. K., Trotta, R., Wlodarski, P., Perrotti, D., Chan, T. O., et al. (1997) · The EMBO Journal · doi:10.1093/emboj/16.20.6151 · Cited by 567
Carroll, M., Ohno-Jones, S., Tamura, S., Buchdunger, E., Zimmermann, J., Lydon, N. B., Gilliland, D. G., & Druker, B. J. (1997) · Blood · doi:10.1182/blood.v90.12.4947 · Cited by 554
Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60784-8 · Cited by 540
Baskaran, R., Wood, L. D., Whitaker, L. L., Canman, C. E., Morgan, S. E., Xu, Y., Barlow, C., Baltimore, D., Wynshaw-Boris, A., Kastan, M. B., et al. (1997) · Nature · doi:10.1038/387516a0 · Cited by 539
Agullo, G., Gamet-Payrastre, L., Manenti, S., Viala, C., Rémésy, C., Chap, H., & Payrastre, B. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)82453-7 · Cited by 536
Combinatorial chemoprevention of intestinal neoplasia
Torrance, C. J., Jackson, P. E., Montgomery, E., Kinzler, K. W., Vogelstein, B., Wissner, A., Nunes, M., Frost, P., & Discafani, C. M. (2000) · Nature Medicine · doi:10.1038/79534 · Cited by 493
Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators
Senderowicz, A. M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.5.376 · Cited by 492
Pollack, V. A., Savage, D. M., Baker, D. A., Tsaparikos, K. E., Sloan, D. E., Moyer, J. D., Barbacci, E. G., Pustilnik, L. R., Smolarek, T. A., Davis, J. A., et al. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35162-6 · Cited by 434
Down-regulation of protein kinase C is due to an increased rate of degradation
Young, S., Parker, P. J., Ullrich, A., & Stabel, S. (1987) · Biochemical Journal · doi:10.1042/bj2440775 · Cited by 430
Structural basis of inhibitor selectivity in MAP kinases
Wang, Z., Canagarajah, B. J., Boehm, J. C., Kassisà, S., Cobb, M. H., Young, P. R., Abdel-Meguid, S., Adams, J. L., & Goldsmith, E. J. (1998) · Structure · doi:10.1016/s0969-2126(98)00113-0 · Cited by 423
Fry, D. W., Bridges, A. J., Denny, W. A., Doherty, A., Greis, K. D., Hicks, J. L., Hook, K. E., Keller, P. R., Leopold, W. R., Loo, J. A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.12022 · Cited by 418
Self-citationWelch, P. (1993) · Cell · doi:10.1016/0092-8674(93)90497-e · Cited by 407
Weisberg, E., & Griffin, J. D. (2000) · Blood · doi:10.1182/blood.v95.11.3498 · Cited by 401
Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer Therapy
Raymond, E., Faivre, S., & Armand, J. P. (2000) · Drugs · doi:10.2165/00003495-200060001-00002 · Cited by 398
Strategies toward the Design of Novel and Selective Protein Tyrosine Kinase Inhibitors
Traxler, P., & Furet, P. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00044-8 · Cited by 388
Horita, M., Andreu, E. J., Benito, A., Arbona, C., Sanz, C., Benet, I., Prosper, F., & Fernandez-Luna, J. L. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.6.977 · Cited by 366
The potential for isoenzyme‐selective modulation of protein kinase C
Hofmann, J. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.8.9240967 · Cited by 340
Jirousek, M. R., Gillig, J. R., Gonzalez, C. M., Heath, W. F., McDonald, J. H., Neel, D. A., Rito, C. J., Singh, U., Stramm, L. E., Melikian-Badalian, A., et al. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm950588y · Cited by 339
Vigneri, P., & Wang, J. Y. J. (2001) · Nature Medicine · doi:10.1038/84683 · Cited by 331
Bridges, A. J., Zhou, H., Cody, D. R., Rewcastle, G. W., McMichael, A., Showalter, H. D. H., Fry, D. W., Kraker, A. J., & Denny, W. A. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9503613 · Cited by 320
Self-citationZD1839 (???Iressa???)*,??? as an Anticancer Agent
Baselga, J., & Averbuch, S. D. (2000) · Drugs · doi:10.2165/00003495-200060001-00004 · Cited by 301
Liang, Y.-C., Lin-shiau, S.-Y., Chen, C.-F., & Lin, J.-K. (1997) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(19971001)67:1<55::aid-jcb6>3.0.co;2-v · Cited by 294
EGF receptor in neoplasia and metastasis
Khazaie, K., Schirrmacher, V., & Lichtner, R. B. (1993) · Cancer and Metastasis Reviews · doi:10.1007/bf00665957 · Cited by 288
Regulation of cell death by the Abl tyrosine kinase
Wang, J. Y. (2000) · Oncogene · doi:10.1038/sj.onc.1203878 · Cited by 278
The nuclear tyrosine kinase c-abl negatively regulates cell growth
Sawyers, C. L., McLaughlin, J., Goga, A., Havlik, M., & Witte, O. (1994) · Cell · doi:10.1016/0092-8674(94)90240-2 · Cited by 275
Smaill, J. B., Rewcastle, G. W., Loo, J. A., Greis, K. D., Chan, O. H., Reyner, E. L., Lipka, E., Showalter, H. D. H., Vincent, P. W., Elliott, W. L., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990482t · Cited by 269
Schulte, T. W., Blagosklonny, M. V., Romanova, L., Mushinski, J. F., Monia, B. P., Johnston, J. F., Nguyen, P., Trepel, J., & Neckers, L. M. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5839 · Cited by 269
The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
Krystal, G. W., Honsawek, S., Litz, J., & Buchdunger, E. (2000) · PubMed · Cited by 265
Rewcastle, G. W., Denny, W. A., Bridges, A. J., Zhou, H., Cody, D. R., McMichael, A., & Fry, D. W. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00018a008 · Cited by 263
Self-citationEpidermal growth factor receptor tyrosine kinase
Ward, W. H. J., Cook, P. N., Slater, A. M., Davies, D. H., Holdgate, G. A., & Green, L. R. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90042-6 · Cited by 261
Newlands, E., Rustin, G., & Brampton, M. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.415 · Cited by 248
Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene
Goga, A., McLaughlin, J., Afar, D. E. H., Saffran, D. C., & Witte, O. N. (1995) · Cell · doi:10.1016/0092-8674(95)90277-5 · Cited by 248
Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives
Zimmermann, J., Buchdunger, E., Mett, H., Meyer, T., & Lydon, N. B. (1997) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(96)00601-4 · Cited by 247
Cell Cycle Molecular Targets in Novel Anticancer Drug Discovery
Buolamwini, J. (2000) · Current Pharmaceutical Design · doi:10.2174/1381612003400948 · Cited by 238
Wang, W.-L., Healy, M. E., Sattler, M., Verma, S., Lin, J., Maulik, G., Stiles, C. D., Griffin, J. D., Johnson, B. E., & Salgia, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203698 · Cited by 234
Shewchuk, L., Hassell, A., Wisely, B., Rocque, W., Holmes, W., Veal, J., & Kuyper, L. F. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990401t · Cited by 233
Bivalence of EGF-like ligands drives the ErbB signaling network
Tzahar, E. (1997) · The EMBO Journal · doi:10.1093/emboj/16.16.4938 · Cited by 228
Amarante-Mendes, G. P., McGahon, A. J., Nishioka, W. K., Afar, D. E., Witte, O. N., & Green, D. R. (1998) · Oncogene · doi:10.1038/sj.onc.1201664 · Cited by 226
The epsilon isoform of protein kinase C is an oncogene when overexpressed in rat fibroblasts.
Am, C., Guadagno, S. N., Rs, K., Fabbro, D., & Ib, W. (1993) · PubMed · Cited by 225
Erlichman, C., Boerner, S. A., Hallgren, C. G., Spieker, R. S., Wang, X., James, C. D., Scheffer, G. L., Maliepaard, M., Ross, D. D., Bible, K. C., et al. (2001) · PubMed · Cited by 224
Wissner, A., Berger, D. M., Boschelli, D. H., Floyd, M. B., Greenberger, L. M., Gruber, B. C., Johnson, B. D., Mamuya, N., Nilakantan, R., Reich, M. F., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000206a · Cited by 207
Tumor Promotion by Depleting Cells of Protein Kinase Cδ
Lu, Z., Hornia, A., Jiang, Y.-W., Zang, Q., Ohno, S., & Foster, D. A. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.6.3418 · Cited by 207
Traxler, P., Bold, G., Frei, J., Lang, M., Lydon, N., Mett, H., Buchdunger, E., Meyer, T., Mueller, M., & Furet, P. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm970124v · Cited by 203
Schnur, R. C., Corman, M. L., Gallaschun, R. J., Cooper, B. A., Dee, M. F., Doty, J. L., Muzzi, M. L., Moyer, J. D., & DiOrio, C. I. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00019a010 · Cited by 199
Protein Kinase InhibitorsThe Tyrosine-Specific Protein Kinases
Lawrence, D. S., & Niu, J. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)00052-1 · Cited by 198
Selective inhibition of the epidermal growth factor and HER2/neu receptors by tyrphostins
Osherov, N., Gazit, A., Gilon, C., & Levitzki, A. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82102-0 · Cited by 195
Sepp-Lorenzino, L., Ma, Z., Lebwohl, D. E., Vinitsky, A., & Rosen, N. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.28.16580 · Cited by 189
Emodin, a Protein Tyrosine Kinase Inhibitor from Polygonum cuspidatum
Jayasuriya, H., Koonchanok, N. M., Geahlen, R. L., McLaughlin, J. L., & Chang, C.-J. (1992) · Journal of Natural Products · doi:10.1021/np50083a026 · Cited by 185
The development and therapeutic potential of protein kinase inhibitors
Cohen, P. (1999) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(99)80067-2 · Cited by 182
Smaill, J. B., Palmer, B. D., Rewcastle, G. W., Denny, W. A., McNamara, D. J., Dobrusin, E. M., Bridges, A. J., Zhou, H., Showalter, H. D. H., Winters, R. T., et al. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9806603 · Cited by 177
Self-citationAtypical Protein Kinase C ι Protects Human Leukemia Cells against Drug-induced Apoptosis
Murray, N. R., & Fields, A. P. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.44.27521 · Cited by 177
Noonberg, S. B., & Benz, C. C. (2000) · Drugs · doi:10.2165/00003495-200059040-00003 · Cited by 173
Zi, X., Grasso, A. W., Kung, H.-J., & Agarwal, R. (1998) · PubMed · Cited by 167
Ubiquitination of Protein Kinase C-α and Degradation by the Proteasome
Lee, H.-W., Smith, L., Pettit, G. R., Vinitsky, A., & Smith, J. B. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.35.20973 · Cited by 163
Inhibition of transforming activity of tyrosine kinase oncogenes by herbimycin A
Uehara, Y., Murakami, Y., Mizuno, S., & Kawalt, S. (1988) · Virology · doi:10.1016/0042-6822(88)90649-6 · Cited by 162
Zhang, L., Chang, C., Bacus, S. S., & Hung, M. (1995) · PubMed · Cited by 162
Rewcastle, G. W., Palmer, B. D., Bridges, A. J., Showalter, H. D. H., Sun, L., Nelson, J. M., McMichael, A., Kraker, A. J., Fry, D. W., & Denny, W. A. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm950692f · Cited by 150
Self-citationSchnur, R. C., Corman, M. L., Gallaschun, R. J., Cooper, B. A., Dee, M. F., Doty, J. L., Muzzi, M. L., DiOrio, C., & Barbacci-Tobin, E. G. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00019a011 · Cited by 141
Chemical inhibitors of cyclin-dependent kinases
Meijer, L., & Kim, S. (1997) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(97)83011-x · Cited by 140
p53 dependent growth suppression by the c-Abl nuclear tyrosine kinase.
Goga, A., Liu, X., Hambuch, T. M., Senechal, K., Major, E., Berk, A. J., Witte, O. N., & Sawyers, C. L. (1995) · PubMed · Cited by 133
Fry, D. W. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00050-3 · Cited by 129
Protein Kinase Cζ Is a Negative Regulator of Protein Kinase B Activity
Doornbos, R. P., Theelen, M., van der Hoeven, P. C. J., BLITTERSWIJK, W. J. V., Verkleij, A. J., & Henegouwen, P. M. P. V. B. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.13.8589 · Cited by 128
ATP site-directed competitive and irreversible inhibitors of protein kinases
Garc�a-Echeverr�a, C., Traxler, P. M., & Evans, D. B. (2000) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(200001)20:1<28::aid-med2>3.0.co;2-2 · Cited by 124
Inactivation of creatine kinase by S-glutathionylation of the active-site cysteine residue
REDDY, S., Jones, A. D., Cross, C. E., Wong, P., & van der Vliet, A. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3470821 · Cited by 124
Morin, M. J. (2000) · Oncogene · doi:10.1038/sj.onc.1204102 · Cited by 120
Rao, G., Murray, S., & Ethier, S. P. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)01358-4 · Cited by 117
Palmer, B. D., Trumpp-Kallmeyer, S., Fry, D. W., Nelson, J. M., Showalter, H. D. H., & Denny, W. A. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960789h · Cited by 115
Rewcastle, G. W., Palmer, B. D., Thompson, A. M., Bridges, A. J., Cody, D. R., Zhou, H., Fry, D. W., McMichael, A., & Denny, W. A. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9508651 · Cited by 114
Self-citationRewcastle, G. W., Murray, D. K., Elliott, W. L., Fry, D. W., Howard, C. T., Nelson, J. M., Roberts, B. J., Vincent, P. W., Showalter, H. D. H., Winters, R. T., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970641d · Cited by 113
Discafani, C. M., Carroll, M. L., Floyd, M. B., Hollander, I. J., Husain, Z., Johnson, B. D., Kitchen, D., May, M. K., Malo, M. S., Minnick, A. A., et al. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00356-6 · Cited by 112
Yoneda, T., Lyall, R. M., Alsina, M. M., Persons, P. E., Spada, A. P., Levitzki, A., Zilberstein, A., & Mundy, G. R. (1991) · PubMed · Cited by 112
Development of inhibitors for protein tyrosine kinases
Al‐Obeidi, F., & Lam, K. S. (2000) · Oncogene · doi:10.1038/sj.onc.1203926 · Cited by 111
Singh, J., Dobrusin, E. M., Fry, D. W., Haske, T., Whitty, A., & McNamara, D. J. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960380s · Cited by 108
Furet, P., Caravatti, G., Lydon, N., Priestle, J. P., Sowadski, J. M., Trinks, U. P., & Traxler, P. M. (1995) · Journal of Computer-Aided Molecular Design · doi:10.1007/bf00124317 · Cited by 108
Klohs, W. D., Fry, D. W., & Kraker, A. J. (1997) · Current Opinion in Oncology · doi:10.1097/00001622-199711000-00012 · Cited by 106
Zou, X., Rudchenko, S., Wong, K., & Calame, K. L. (1997) · Genes & Development · doi:10.1101/gad.11.5.654 · Cited by 106
c-Abl Neutralizes the Inhibitory Effect of Mdm2 on p53
Sionov, R. V., Moallem, E., Berger, M., Kazaz, A., Gerlitz, O., Ben‐Neriah, Y., Oren, M., & Haupt, Y. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.13.8371 · Cited by 104
The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer
Gullick, W. J., & Srinivasan, R. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006107016969 · Cited by 103
Waterman, H., Alroy, I., Strano, S., Seger, R., & Yarden, Y. (1999) · The EMBO Journal · doi:10.1093/emboj/18.12.3348 · Cited by 103
Staurosporine analogues — pharmacological toys or useful antitumour agents?
Gescher, A. J. (2000) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00058-5 · Cited by 103
Rewcastle, G. W., Bridges, A. J., Fry, D. W., Rubin, J. R., & Denny, W. A. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960879m · Cited by 100
Self-citationTrinks, U. P., Buchdunger, E., Furet, P., Kump, W. G., Mett, H., Meyer, T., Mueller, M., Regenass, U., & RIHS, G. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00033a019 · Cited by 91
Synthesis and Src Kinase Inhibitory Activity of a Series of 4-Phenylamino-3-quinolinecarbonitriles
Boschelli, D. H., Wang, Y. D., Ye, F., Wu, B., Zhang, N., Dutia, M. D., Powell, D. W., Wissner, A., Arndt, K. T., Weber, J. M., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm000420z · Cited by 91
Kinase Inhibitors in Cancer Therapy: A Look Ahead
Sedlacek, H. H. (2000) · Drugs · doi:10.2165/00003495-200059030-00004 · Cited by 90
Inhibitors of p38 MAP Kinase: Therapeutic Intervention in Cytokine-Mediated Diseases
Salituro, F. G., Germann, U. A., Wilson, K. P., Bemis, G. W., Fox, T., & Su, M. S. S. (1999) · Current Medicinal Chemistry · doi:10.2174/092986730609220401150415 · Cited by 87
Copp, B. R., Fairchild, C. R., Cornell, L., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980294n · Cited by 85
Protein Kinase C Targeting in Antineoplastic Treatment Strategies
Jarvis, W. D., & Grant, S. (1999) · Investigational New Drugs · doi:10.1023/a:1006328303451 · Cited by 84
Zheng, F. F., Kuduk, S. D., Chiosis, G., Münster, P. N., Sepp‐Lorenzino, L., Danishefsky, S. J., & Rosen, N. X. (2000) · PubMed · Cited by 81
Boehm, J. C., & Adams, J. L. (2000) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.10.1.25 · Cited by 80
Gescher, A. J. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.209 · Cited by 80
Cyclin-dependent kinase inhibitors: novel anticancer agents
Mani, S., Wang, C., Wu, K., Francis, R., & Pestell, R. G. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.8.1849 · Cited by 80
Marley, S. B., Deininger, M. W., Davidson, R. J., Goldman, J. M., & Gordon, M. Y. (2000) · Experimental Hematology · doi:10.1016/s0301-472x(00)00142-9 · Cited by 79
Receptor tyrosine kinases as targets for inhibition of angiogenesis
Shawver, L. K., Lipson, K. E., Fong, T. A. T., McMahon, G., Plowman, G. D., & Strawn, L. M. (1997) · Drug Discovery Today · doi:10.1016/s1359-6446(96)10053-2 · Cited by 79
Voss, J., Posern, G., Hannemann, J., Wiedemann, L. M., Turhan, A. G., Poirel, H. A., Bernard, O., Adermann, K., Kardinal, C., & Feller, S. M. (2000) · Oncogene · doi:10.1038/sj.onc.1203467 · Cited by 77
Protein tyrosine kinase inhibitors in cancer treatment
Traxler, P. M. (1997) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.7.6.571 · Cited by 75
Protein kinase inhibitors: emerging pharmacophores 1997 - 2000
Dumas, J. (2001) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.11.3.405 · Cited by 71
Wang, Y. D., Miller, K., Boschelli, D. H., Ye, F., Wu, B., Floyd, M. B., Powell, D. W., Wissner, A., Weber, J. M., & Boschelli, F. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00493-5 · Cited by 70
Small molecule inhibitors of receptor tyrosine kinases
Boschelli, D. H. (1999) · Drugs of the Future · doi:10.1358/dof.1999.024.05.858622 · Cited by 70
Inhibition of epidermal growth factor receptor tyrosine kinase activity by hypericin
de Witte, P. A. M., Agostinis, P., Lint, J. V., Merlevede, W. J., & Vandenheede, J. R. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90633-8 · Cited by 69
Tyrosine kinase inhibitors in cancer treatment (Part II)
Traxler, P. M. (1998) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.8.12.1599 · Cited by 68
Hamby, J. M., & Showalter, H. D. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00053-9 · Cited by 66
Toledo, L. M., & Lydon, N. (1997) · Structure · doi:10.1016/s0969-2126(97)00304-3 · Cited by 65
Fry, D. W., Nelson, J. M., Slintak, V., Keller, P. R., Rewcastle, G. W., Denny, W. A., Zhou, H., & Bridges, A. J. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00242-6 · Cited by 65
Self-citationCong, F., & Goff, S. P. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.13819 · Cited by 64
Mehta, P., Patel, K. D., Laue, T. M., Erickson, H., & McEver, R. P. (1997) · Blood · doi:10.1182/blood.v90.6.2381 · Cited by 63
Kunkel, M. W., Hook, K. E., Howard, C. T., Przybranowski, S. A., Roberts, B. J., Elliott, W. L., & Leopold, W. R. (1995) · Investigational New Drugs · doi:10.1007/bf00873135 · Cited by 59
Tyrosine Kinase Inhibitors in Preclinical Development
Levitt, M. L., & Koty, P. P. (1999) · Investigational New Drugs · doi:10.1023/a:1006372102543 · Cited by 58
Thompson, A. M., Murray, D. K., Elliott, W. L., Fry, D. W., Nelson, J. A., Showalter, H. D. H., Roberts, B. J., Vincent, P. W., & Denny, W. A. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm970366v · Cited by 57
(1999) · doi:10.1093/oso/9780199637294.001.0001 · Cited by 57
Gibson, K. H., Grundy, W., Godfrey, A. A., et al. (1997) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(97)10059-2 · Cited by 55
Protein kinase inhibition: natural and synthetic variations on a theme
Taylor, S. S., & Radzio-Andzelm, E. (1997) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(97)80013-0 · Cited by 54
Chopra, R., Pu, Q. Q., & Elefanty, A. G. (1999) · Blood Reviews · doi:10.1054/blre.1999.0119 · Cited by 53
Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia
Goldman, J. M. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02029-8 · Cited by 51
Zhang, N., Wu, B., Powell, D. W., Wissner, A., Floyd, M. B., Kovacs, E. D., Toral‐Barza, L., & Kohler, C. A. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00580-1 · Cited by 49
Hinterding, K., Knebel, A., Herrlich, P., & Waldmann, H. (1998) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(98)00070-4 · Cited by 48
Vincent, P. W., Bridges, A. J., Dykes, D. J., Fry, D. W., Leopold, W. R., Patmore, S. J., Roberts, B. J., Rose, S., Sherwood, V., Zhou, H., et al. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050034 · Cited by 47
Self-citationMiller, P. E., Schnur, R. C., Barbacci-Tobin, E. G., Moyer, M. P., & Moyer, J. D. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1847 · Cited by 47
Photodynamic effects of haematoporphyrin derivative on DNA repair in murine L929 fibroblasts
Boegheim, J. P. J., Dubbelman, T. M. A. R., Mullenders, L. H. F., & Steveninck, J. V. (1987) · Biochemical Journal · doi:10.1042/bj2440711 · Cited by 45
Myers, M. R., Setzer, N. N., Spada, A. P., Zulli, A. L., Hsu, C.-Y. J., Zilberstein, A., Johnson, S. E., Hook, L. E., & Jacoski, M. V. (1997) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(97)00034-6 · Cited by 45
Supino‐Rosin, L., Yoshimura, A., Yarden, Y., Elazar, Z., & Neumann, D. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001834200 · Cited by 44
[32] Use of erbstatin as protein-tyrosine kinase inhibitor
Umezawa, K., & Imoto, M. (1991) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(91)01034-y · Cited by 39
Protein kinase C-zeta reverts v-raf transformation of NIH-3T3 cells.Preprint
Kieser, A., Seitz, T., Adler, H. S., Coffer, P. J., Elisabeth, K., Crespo, P., Gutkind, J. S., Henderson, D. W., Mushinski, J. F., Kölch, W., et al. (1996) · Genes & Development · doi:10.1101/gad.10.12.1455 · Cited by 39
Murakami, Y., Mizuno, S., & Uehara, Y. (1994) · Biochemical Journal · doi:10.1042/bj3010063 · Cited by 38
Targeting hyperproliferative disorders with cyclin dependent kinase inhibitors
Rosania, G. R., & Chang, Y. (2000) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.10.2.215 · Cited by 36
Showalter, H. D., & Kraker, A. J. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)00097-1 · Cited by 34
Lydon, N., Mett, H., Mueller, M. R., Becker, M. A., Cozens, R. M., Stover, D. R., Daniels, D., Traxler, P. M., & Buchdunger, E. (1998) · International Journal of Cancer · Cited by 27
Donato, N. J., & Talpaz, M. (2000) · PubMed · Cited by 27
Bridges, A. J., Cody, D. R., Zhou, H., McMichael, A., & Fry, D. W. (1995) · Bioorganic & Medicinal Chemistry · doi:10.1016/0968-0896(95)00149-2 · Cited by 25
Self-citationKakeya, H., Imoto, M., Tabata, Y., Iwami, J., Matsumoto, H., Nakamura, K., Koyano, T., Tadano, K., & Umezawa, K. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)80085-9 · Cited by 24
Gill, G. N., & Weber, W. (1987) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(87)46010-2 · Cited by 22
In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022
McLeod, H., Brunton, V., Eckardt, N., Lear, M. J., Robins, D., Workman, P., & Graham, M. A. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.620 · Cited by 22
Okabe, T., Yoshida, E., Chieda, S., ENDO, K., Kamiya, S., OSADA, K., Tanaka, S., Okura, A., & Suda, H. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.289 · Cited by 15
Recent developments in protein kinase C inhibitors
Harris, W. R., Wilkinson, S., & Nixon, J. (1997) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.7.1.63 · Cited by 13
BE‐23372M, a Novel and Specific Inhibitor for Epidermal Growth Factor Receptor Kinase
Tanaka, S., Okabe, T., Chieda, S., Endo, K., Kanoh, T., Okura, A., & Yoshida, E. (1994) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1994.tb02090.x · Cited by 11
A Tyrphostin-Derived Inhibitor of Protein Tyrosine Kinases: Isolation and Characterization
Ramdas, L., Obeyesekere, N., McMurray, J. S., Gallick, G. E., Seifert, W. E., & Budde, R. J. A. (1995) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1995.9969 · Cited by 10
Selective tyrosine kinase inhibitors
Wilkinson, S. E., & Harris, W. R. (2000) · Emerging Drugs · doi:10.1517/14728214.5.3.287 · Cited by 8
Cited by
Stamos, J., Sliwkowski, M. X., & Eigenbrot, C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207135200 · Cited by 1,574
Fluorine in medicinal chemistry: A review of anti-cancer agents
Isanbor, C., & O’Hagan, D. (2006) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2006.01.011 · Cited by 1,120
Anti-cancer potential of flavonoids: recent trends and future perspectives
Batra, P., & Sharma, A. K. (2013) · 3 Biotech · doi:10.1007/s13205-013-0117-5 · Cited by 550
Inhibitors of Protein Tyrosine Phosphatases: Next‐Generation Drugs?
Bialy, L., & Waldmann, H. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200461517 · Cited by 420
Important fluorinated drugs in experimental and clinical use
Ismail, F. M. D. (2002) · Journal of Fluorine Chemistry · doi:10.1016/s0022-1139(02)00201-4 · Cited by 398
Metadata
- Authors
- Bridges, A. J.
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 2001-07-04
- Volume
- 101
- Issue
- 8
- Pages
- 2541-2572
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- OpenAlex
- W2034919226
- Cited by
- 320
- References
- 165
- FWCI
- 1.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.